Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 18 for:    alpharadin | Open Studies
Previous Study | Return to List | Next Study

Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL) (EIFFEL)

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified July 2016 by Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Sponsor:
Information provided by (Responsible Party):
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
ClinicalTrials.gov Identifier:
NCT02880943
First received: August 18, 2016
Last updated: August 26, 2016
Last verified: July 2016
  Purpose
This is a prospective, multicentre, open-label, phase I/II study to evaluate the maximum tolerated dose (MTD), and the most successful dose (MSD) of XOFIGO®, in renal cancer patients with metastases to bone, without (Group A) or with (Group B) visceral metastases.

Condition Intervention Phase
Clear-cell Metastatic Renal Cell Carcinoma
Bone Metastases
Drug: XOFIGO
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO®) in Renal Cell Carcinoma Patients With Bone Metastases.

Resource links provided by NLM:


Further study details as provided by Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie:

Primary Outcome Measures:
  • Dose-limiting toxicities (DLT) [ Time Frame: within 6 weeks after the first injection of XOFIGO ] [ Designated as safety issue: Yes ]

    Dose-limiting toxicities (DLT) within the first 6 weeks to determine the MTD.

    DLT is defined as any XOFIGO related adverse event occurring between C1D1 and C2D15.



Secondary Outcome Measures:
  • Distribution of radium-223 dichloride into the bone assessed with scintigraphy of biodistribution of radium-223 dichloride [ Time Frame: Assessed at day 1 after the first Xofigo injection ] [ Designated as safety issue: No ]
    Distribution of radium-223 dichloride into the bone assessed with scintigraphy of biodistribution of radium-223 dichloride

  • Bone response concordance between FNa-PET scan and whole-body MRI [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  • Bone clinical benefit rate (bone objective response or stable disease, BCB) [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  • Overall clinical benefit rate (bone and visceral objective response or stable disease, OCB) [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  • Changes in bone markers [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
    Changes in bone markers: bone formation: bone alkaline phosphatase [bALP], N-terminal type I collagen [PINP]; bone resorption: C-terminal telopeptide cross-linking of type I collagen [S-CTX-I], cross-linked C-terminal telopeptide of type I collagen [ICTP]), TRACP 5b, sRANKL, osteoprotegerin (OPG)

  • Time to occurrence of the first Skeletal-Related Events (SRE) [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
    SRE including pathological fracture, requirement to initiate radiotherapy, spinal cord compression or requirement for bone surgery

  • Time to bone progression (TTBP) defined as the time from the first administration of XOFIGO® to the bone tumour progression (revised RECIST 1.1 taking into account bone lesions) [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]
  • 1-year overall survival rate (1y-OS) defined as the percentage of patients alive 1 year after 1st administration of XOFIGO® [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • Pain assessment upon Brief Pain Inventory (BPI) and analgesic consumption questionnaire [ Time Frame: BPI questionnaire will be completed 7 days before the first administration of XOFIGO® and before each visit. ] [ Designated as safety issue: No ]
  • Change From Baseline in the FACT-Kidney Symptom Index-15 (FKSI-15) Scale [ Time Frame: 7 months (Baseline and at 7 months) ] [ Designated as safety issue: No ]
    FKSI-15 questionnaire will be performed only for patients included in the phase II part of the study.

  • Changes in MRI [ Time Frame: up to 12 months ] [ Designated as safety issue: No ]

    New MRI criteria as prediction markers for progression and for disease specific and overall survival:

    Diffusion weighted imaging (DWI): Apparent diffusion coefficient (ADC) values in the five target bone lesions

    • Ultra-short echo time (UTE) sequence: T2 measurements in the five target bone lesions
    • Perfusion weighted imaging (PWI): assessments of the area under the curve at 1min30, and of the focal lesion (FLE max) enhancement.

  • Change From Baseline in EQ-5D Scale [ Time Frame: 7 months (Baseline and at 7 months) ] [ Designated as safety issue: No ]
    EQ-5D questionnaire will be performed only for patients included in the phase II part of the study.


Estimated Enrollment: 42
Study Start Date: September 2016
Estimated Study Completion Date: February 2021
Estimated Primary Completion Date: September 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Group A

Group A: patients with bone disease mainly will be treated with XOFIGO® alone.

Node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A.

Drug: XOFIGO

XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.

Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.

Starting dose for phase I will be 55 kBq/kg.

Other Name: radium-223
Experimental: Group B
Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.
Drug: XOFIGO

XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.

Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.

Starting dose for phase I will be 55 kBq/kg.

Other Name: radium-223

Detailed Description:

This is a prospective, multicentre, open-label, phase I/II study to evaluate the maximum tolerated dose (MTD), and the most successful dose (MSD) of XOFIGO®, in renal cancer patients with metastases to bone, without (Group A) or with (Group B) visceral metastases.

Dose-finding will be performed according to the Continual Reassessment Method (CRM) using either toxicity (escalation cohort) or joined toxicity-efficacy (expansion cohort) endpoints.

Two groups of patients will be evaluated:

  • Group A: patients with bone disease mainly will be treated with XOFIGO® alone. (node and/or adrenal metastases and/or ≤5 lung metastases ≤1cm each are allowed in Group A).
  • Group B: patients already treated with an ongoing approved Tyrosine Kinase Inhibitor (TKI) for their visceral metastases will be treated with XOFIGO® for bone disease.

XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient. Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.

Starting dose for phase I will be 55 kBq/kg.

Visit schedule:

Selection Patients will come to the hospital at baseline, and screening assessments must be performed within 28 days prior to first XOFIGO® administration.

XOFIGO® period Patients will receive an injection of XOFIGO® on Day 1 of each 4 weeks-cycle for a maximum of 6 cycles. Patients will be subject to physical examination, blood sampling and pain evaluation prior to each injection. Scintigraphy of biodistribution of radium-223 dichloride will be realised on C1D1 after the 1st injection of XOFIGO® On C1D15, patients will also come for physical examination and blood sampling. On C2D15 (end of DLT period for phase I), patients will also come for end of DLT period evaluation and will be subject to physical examination and blood sampling.

Prior to C3D1 and C5D1, patients will undergo WB-IRM and FNa-PET. End of treatment visit (EOT) will take place 4 weeks after the last administration of XOFIGO®.

In the absence of confirmed bone progression at XOFIGO® discontinuation time, patients will continue to undergo WB-IRM and FNa-PET every 2 months until confirmed bone progression or end of follow-up.

Confirmation of bone progression upon WB-IRM will be performed 4 weeks after the initial progression is observed.

Follow-up Patients will be followed-up for a maximum of 12 months from the 1st administration of XOFIGO®.

Number of subjects:

Maximum number of patients to be enrolled in the escalation cohort is 21. Maximum number of patients to be enrolled in the expansion cohort is 21. Group A: 2-4 patients; Group B: 38-40 patients.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically confirmed metastatic renal cell carcinoma with a clear cell component.
  2. Bone metastases upon bone scan with no CT and MRI performed any time within period of 4 weeks prior to study entry, with at least one evaluable unidimensional bone lesion (i.e., ≥1 malignant tumour mass that can be accurately measured in at least 1 dimension ≥ 10 mm on T1-weighted Magnetic Resonance Imaging [MRI]).

    Group A: bone metastases (lymph nodes and/or adrenal metastases, and/or ≤ 5 lung metastases of less than 1 cm each, are allowed).

    Group B: bone metastases AND visceral metastases upon MRI (according to revised RECIST 1.1 criteria).

  3. Patient in a) first (naïve), or b) second or third line setting receiving or about to receive an approved Tyrosine Kinase Inhibitor (patients on mTOR inhibitors are not eligible).
  4. Male or female, age ≥18 years at ICF signature time.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  6. Good or Intermediate prognostic group according to the International Metastatic Database Consortium (IMDC).
  7. At least 4 weeks from the end of a previous systemic treatment, if any, with resolution of all treatment-related toxicity according to NCI CTCAE Version 4.03 grade ≤ 1 except for alopecia.
  8. Palliative local treatment allowed if performed ≥ 2 weeks prior to study entry for radiotherapy, cementoplasty or minor surgery; ≥ 4 weeks prior to study entry for major surgery.
  9. Adequate organ function defined by the following criteria:

    • Absolute Neutrophils count (ANC) ≥1 500 cells/mm3
    • Platelets ≥100 000 cells/mm3
    • Haemoglobin ≥ 9.0 g/dL
    • AST and ALT ≤ 2.5 x upper limit of normal (ULN), unless there are liver metastases in which case AST and ALT ≤5.0 x ULN
    • Total bilirubin ≤ 1.5 x ULN
    • Estimated glomerular filtration rate upon MDRD ≥ 50 mL/min
    • Urinary protein < 2+ by urine dipstick. If dipstick is ≥ 2+ then a 24-hour urine collection can be done and the patient may enter only if urinary protein is < 2 g per 24 hours
    • Corrected calcium ≤ 2.8 mmol/L.
  10. Women of childbearing potential must have a negative serum pregnancy test within 7days prior to treatment initiation.
  11. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrolment.
  12. Willingness, for men and women,to use effective contraception during study treatment and for 6 months after last dose of study drug.
  13. Willingness to comply with protocol requirements.

Exclusion Criteria:

Poor prognostic group according to the IMDC. 2. Prior radiotherapy to ≥ 40% of bone marrow, whole pelvic irradiation and/or prior isotope therapy whatever the isotope (any α- or β-emitters).

3. Active secondary cancer including prior malignancy from which the subject has been disease-free for ≤ 3 years (however, adequately treated superficial basal cell skin or cervical carcinoma in situ before 4 weeks prior to entry are eligible to the study).

4. Known brain or leptomeningeal involvement. 5. Any other concurrent serious illness or medical conditions including:

  • Crohn‟s disease or ulcerative colitis
  • Bone marrow dysplasia
  • Known presence of osteonecrosis of the jaw 6. Uncontrolled hypertension. 7. Uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension. History of congestive heart failure, or myocardial infarction within the last 6 months.

    8. QTc interval (QTc) assessed by local device > 500ms in the 7 days prior to inclusion.

    9. Ongoing biphosphonates, denosumab and/or vitamin D supplementation. 10. Active infection requiring systemic antibiotic or anti-fungal medication. 11. Any contra-indication to MRI, including:

  • Carrying a metallic medical device (e.g. pacemaker) or foreign body prohibiting use of MRI
  • Known allergy to gadolinium or iodine
  • Dysthyroidism precluding usage of iodine contrast agent 12. Pregnant or breast feeding. 13. Participation in another clinical trial with any investigational drug within 30 days prior to study enrolment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02880943

Contacts
Contact: Reza ELAIDI, PhD 00 33 1 56 09 23 40 reza-thierry.elaidi-ext@aphp.fr
Contact: Elena BRAYCHENKO, MD 00 33 1 56 09 34 34 elena.braychenko-ext@aphp.fr

Locations
France
CHU Bordeaux (St. André) Not yet recruiting
Bordeaux, France, 33000
Contact: Alain RAVAUD, MD       alain.ravaud@chu-bordeaux.fr   
Centre François Baclesse Not yet recruiting
Caen, France, 14000
Contact: Florence JOLY, MD       f.joly@baclesse.unicancer.fr   
Hôpital Cochin Not yet recruiting
Paris, France, 75014
Contact: Olivier Huillard, MD       olivier.huillard@cch.aphp.fr   
Hopital Europeen Georges Pompidou Not yet recruiting
Paris, France, 75015
Contact: Stéphane OUDARD, MD       stephane.oudard@aphp.fr   
Institut Gustave Roussy
Villejuif, France, 94805 cedex
Sponsors and Collaborators
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Investigators
Principal Investigator: Stephane OUDARD, MD Hôpital Européen Georges Pompidou, Oncology Department
  More Information

Responsible Party: Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
ClinicalTrials.gov Identifier: NCT02880943     History of Changes
Other Study ID Numbers: EIFFEL 
Study First Received: August 18, 2016
Last Updated: August 26, 2016
Health Authority: France: Agence Nationale de Sécurité du Médicament et des produits de santé
France: Ethics Committee
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Carcinoma
Neoplasm Metastasis
Carcinoma, Renal Cell
Bone Neoplasms
Bone Marrow Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplastic Processes
Pathologic Processes
Adenocarcinoma
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Kidney Diseases
Urologic Diseases
Bone Diseases
Musculoskeletal Diseases
Hematologic Diseases
Radium Ra 223 dichloride
Succinylcholine
Antineoplastic Agents
Neuromuscular Depolarizing Agents
Neuromuscular Blocking Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 26, 2016